Astrazeneca PLC Company Profile (NYSE:AZN)

About Astrazeneca PLC

Astrazeneca PLC logoAstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company's pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, among others.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: AZN
  • CUSIP:
Key Metrics:
  • Previous Close: $30.08
  • 50 Day Moving Average: $32.481
  • 200 Day Moving Average: $30.997
  • 52-Week Range: $26.97 - $35.04
  • Trailing P/E Ratio: 34.029
  • Foreward P/E Ratio: 11.12
  • P/E Growth: -10.060
  • Market Cap: $75.33B
  • Outstanding Shares: 2,530,000,000
  • Beta: 0.75
  • Net Margins: 9.23%
  • Return on Equity: 28.02%
  • Return on Assets: 7.83%
  • Debt-to-Equity Ratio: 1.07%
  • Current Ratio: 0.93%
  • Quick Ratio: 0.76%
Additional Links:
Companies Related to Astrazeneca PLC:

Analyst Ratings

Consensus Ratings for Astrazeneca PLC (NYSE:AZN) (?)
Ratings Breakdown: 2 Sell Ratings, 8 Hold Ratings, 10 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Hold (Score: 2.48)
Consensus Price Target: $37.56 (26.08% upside)

Analysts' Ratings History for Astrazeneca PLC (NYSE:AZN)
DateFirmActionRatingPrice TargetDetails
10/10/2016Deutsche Bank AGReiterated RatingBuyView Rating Details
10/9/2016Leerink SwannReiterated RatingHold$35.00View Rating Details
10/8/2016Shore CapitalReiterated RatingHoldView Rating Details
10/4/2016Bank of America Corp.Set Price TargetBuy$41.00View Rating Details
10/5/2016Goldman Sachs Group Inc.Reiterated RatingSellView Rating Details
10/4/2016Cantor FitzgeraldReiterated RatingBuyView Rating Details
9/23/2016Citigroup Inc.Reiterated RatingBuyView Rating Details
9/23/2016Piper Jaffray Cos.Initiated CoverageOverweightView Rating Details
9/13/2016BNP ParibasDowngradeOutperform -> NeutralView Rating Details
9/12/2016Jefferies GroupUpgradeHold -> BuyView Rating Details
9/11/2016Berenberg BankReiterated RatingBuyView Rating Details
8/29/2016ArgusUpgradeHold -> Buy$38.00View Rating Details
8/26/2016Beaufort SecuritiesReiterated RatingHoldView Rating Details
8/8/2016JPMorgan Chase & Co.Reiterated RatingNeutralView Rating Details
2/28/2016Drexel HamiltonInitiated CoverageBuyView Rating Details
2/8/2016HSBCDowngradeBuy -> HoldView Rating Details
2/5/2016Sanford C. BernsteinLower Price Target$34.00 -> $32.00View Rating Details
1/26/2016Oddo SecuritiesUpgradeNeutral -> Top PickView Rating Details
1/19/2016Barclays PLCUpgradeUnderweight -> Equal Weight$44.00 -> $50.00View Rating Details
1/13/2016Credit Suisse Group AGReiterated RatingUnderperformView Rating Details
12/30/2015Morgan StanleyReiterated RatingBuyView Rating Details
11/2/2015Nordea Equity ResearchDowngradeBuy -> HoldView Rating Details
9/18/2015Bryan, Garnier & CoUpgradeNeutral -> BuyView Rating Details
7/31/2015S&P Equity ResearchUpgradeBuy$38.00View Rating Details
7/31/2015SwedbankUpgradeNeutral -> BuyView Rating Details
6/2/2015Kepler Capital MarketsReiterated RatingReduceView Rating Details
4/16/2015Liberum CapitalReiterated RatingBuyView Rating Details
4/15/2015Societe GeneraleInitiated CoverageBuyView Rating Details
2/6/2015Panmure GordonReiterated RatingBuyView Rating Details
2/6/2015DanskeDowngradeSellView Rating Details
2/3/2015SEB Equity ResearchUpgradeHold -> BuyView Rating Details
(Data available from 10/25/2014 forward)


Earnings History for Astrazeneca PLC (NYSE:AZN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/28/2016Q216$0.76$0.83$5.56 billion$5.60 billionViewListenView Earnings Details
4/29/2016Q1$0.60$0.51$5.96 billion$6.12 billionViewListenView Earnings Details
2/4/2016Q415$0.88$0.94$6.27 billion$6.40 billionViewN/AView Earnings Details
11/5/2015Q315$0.51$1.03$5.90 billion$5.85 billionViewN/AView Earnings Details
7/30/2015Q2$1.08$1.21$6.02 billion$5.84 billionViewListenView Earnings Details
4/24/2015Q1$1.07$1.08$5.87 billion$6.06 billionViewN/AView Earnings Details
2/5/2015Q314$0.85$0.76$6.68 billion$6.68 billionViewN/AView Earnings Details
11/6/2014Q3$1.04$1.05$6.44 billion$6.54 billionViewN/AView Earnings Details
7/31/2014Q214$1.09$1.30$6.24 billion$6.45 billionViewN/AView Earnings Details
4/24/2014Q114$1.23$1.17$6.32 billion$6.42 billionViewN/AView Earnings Details
2/6/2014Q413$1.22$1.23$6.91 billion$3.84 billionViewN/AView Earnings Details
10/31/2013Q313$1.27$1.21$6.45 billion$6.25 billionViewN/AView Earnings Details
8/1/2013Q213$1.16$1.20$6.24 billion$6.23 billionViewN/AView Earnings Details
4/25/2013$1.36$1.41$6.54 billion$6.39 billionViewN/AView Earnings Details
1/31/2013Q412$1.37$1.56$7.17 billion$7.28 billionViewN/AView Earnings Details
10/25/2012$1.44$1.51ViewN/AView Earnings Details
7/26/2012$1.38$1.53ViewN/AView Earnings Details
4/26/2012$1.73$1.81ViewN/AView Earnings Details
2/2/2012$1.57$1.61ViewN/AView Earnings Details
10/27/2011$1.64$1.71ViewN/AView Earnings Details
7/28/2011$1.74$1.53ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Astrazeneca PLC (NYSE:AZN)
Current Year EPS Consensus Estimate: $2.99 EPS
Next Year EPS Consensus Estimate: $2.68 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$0.53$1.01$0.77
Q2 20162$0.40$0.45$0.43
Q3 20162$0.47$0.51$0.49
Q4 20161$0.60$0.60$0.60
(Data provided by Zacks Investment Research)


Current Dividend Information for Astrazeneca PLC (NYSE:AZN)
Annual Dividend:$1.37
Dividend Yield:4.60%
Dividend Growth:-6.60% (3 Year Average)
Payout Ratio:78.29% (Based on Trailing 12 Months of Earnings)
45.82% (Based on Current Year Consensus EPS Estimate)
51.12% (Based on Next Year Consensus EPS Estimate)

Dividend History for Astrazeneca PLC (NYSE:AZN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Astrazeneca PLC (NYSE:AZN)
No insider trades for this company have been tracked by


Latest Headlines for Astrazeneca PLC (NYSE:AZN)
DateHeadline logo6 Big Pharma Companies Left To Report September Quarterly Figures - Benzinga (NYSE:AZN) - October 25 at 3:44 PM
News IconMarket Focus: Checking Indicators on Shares of AstraZeneca PLC (AZN.L) - Hot Stock News (NYSE:AZN) - October 25 at 3:44 PM
News IconToday's Top Gainers in the Market AstraZeneca PLC (NYSE:AZN) from Healthcare - The Daily Leicester (NYSE:AZN) - October 24 at 3:42 PM logoEuropean shares steady, buoyed by bank rally; Spain outperforms (NYSE:AZN) - October 24 at 3:42 PM
News IconHanson & Doremus Investment Management reached $997000 position of Astrazeneca PLC (AZN) - DailyQuint (NYSE:AZN) - October 22 at 3:40 PM
News IconAstraZeneca plc (AZN) – Investment Analysts' Weekly Ratings ... - DailyQuint (NYSE:AZN) - October 22 at 3:40 PM
News IconAstrazeneca PLC (AZN) Stake Increased by Bank of Hawaii - DailyQuint (NYSE:AZN) - October 22 at 3:40 PM
News IconAstraZeneca PLC (NYSE:AZN) from Drug Manufacturers – Major – Todays Top Gains (NYSE:AZN) - October 21 at 8:42 PM
News IconAstraZeneca plc (ADR) (NYSE:AZN): Merrill Lynch Lowers Estimates, Reiterates Buy - Smаrt Stоck Nеws (NYSE:AZN) - October 21 at 3:41 PM logoHere's how a $50 drug ends up costing you $700 in America's healthcare system (NYSE:AZN) - October 21 at 3:41 PM
News IconGlencore PLC (GLEN) And AstraZeneca plc (AZN): It's Not Over Yet For Brexit's Biggest Winners - Simply Wall St (NYSE:AZN) - October 20 at 9:36 AM logoDrug Wars: California Vote Could Limit Price Hikes (NYSE:AZN) - October 19 at 4:32 PM
News IconUpdate on AstraZeneca PLC (NYSE:AZN) for the day (NYSE:AZN) - October 19 at 8:36 AM logoAstraZeneca Plc : AZN-US: Dividend Analysis : August 12th, 2016 (record date) : By the numbers : October 18, 2016 (NYSE:AZN) - October 18 at 3:41 PM logoAstraZeneca: FDA to review hyperkalaemia drug - MarketWatch (NYSE:AZN) - October 18 at 8:32 AM
News IconInvestor Market Move: Cypress Asset Management INC Holding in Astrazeneca Plc (AZN) Decreased by $3.08 Million ... - Chester News (NYSE:AZN) - October 18 at 8:32 AM
News IconLeading stocks in today’s market: AstraZeneca PLC (NYSE:AZN) (NYSE:AZN) - October 17 at 3:40 PM logoAstraZeneca Plc (NYSE:AZN) Sends Synairgen Plummeting On Ditching Asthma Drug Trial - Market Exclusive (NYSE:AZN) - October 17 at 8:34 AM logoWhite House To Announce Big Push For Cancer Blood Tests (NYSE:AZN) - October 17 at 8:34 AM
News IconActive Wrathful Watching Stock: Novavax, Inc. (NASDAQ:NVAX), AstraZeneca PLC (NYSE:AZN) - Street Wise Report (press release) (blog) (NYSE:AZN) - October 15 at 8:34 AM
News IconAstraZeneca PLC's (AZN): Effective Mover to See - Hot Stocks Point (NYSE:AZN) - October 15 at 8:34 AM
News IconStocks Difficult to Chew Analyst Recom- AstraZeneca PLC (NYSE:AZN), Tesaro, Inc. (NASDAQ:TSRO) - Seneca Globe (NYSE:AZN) - October 14 at 3:42 PM logoAstraZeneca Plc (ADR) (AZN) Offloads Two Diabetes Drugs to Focus on Core Therapeutic Areas (NYSE:AZN) - October 14 at 3:42 PM logoAstraZeneca Plc (NYSE:AZN) Offloads Two Diabetes Drugs to Focus on Core Therapeutic Areas (NYSE:AZN) - October 14 at 12:08 PM logoForget short term pain! Buy these FTSE 100 stars for long-term gain (NYSE:AZN) - October 14 at 12:08 PM logoHow Much Is Pfizer’s Return Potential? (NYSE:AZN) - October 14 at 12:08 PM logoSynairgen: AstraZeneca stopped asthma drug trial - MarketWatch (NYSE:AZN) - October 12 at 8:06 AM
News IconStocks having Bumpy Ride for the Day: AstraZeneca PLC (NYSE:AZN), Agilent Technologies, Inc. (NYSE:A) - Street Wise Report (press release) (blog) (NYSE:AZN) - October 11 at 3:48 PM logoIs It Time To Consider AstraZeneca? - Seeking Alpha (NYSE:AZN) - October 11 at 3:48 PM logoIntelliPharmaCeutics Soars on Tentative FDA Approval (NYSE:AZN) - October 10 at 3:40 PM logoFulvestrant Demonstrates Progression-Free Survival Advantage in 1st Line Advanced Breast Cancer (NYSE:AZN) - October 8 at 8:30 AM logo3 Big Stock Charts: Chesapeake Energy Corporation (CHK), AstraZeneca plc (ADR) (AZN) and Groupon Inc (GRPN) - (NYSE:AZN) - October 7 at 3:43 PM logoClovis Falls on Fears Ovarian Cancer Drug Inferior to Competition (NYSE:AZN) - October 7 at 3:43 PM logoClovis Nose-Dives On Potentially Inferior Cancer Drug Vs. AstraZeneca (NYSE:AZN) - October 7 at 3:43 PM logoAstrazeneca In Deal With JNJ Unit To Divest Rights To Rhinocort Aqua Outside US (NYSE:AZN) - October 7 at 8:32 AM logoHere is Why AstraZeneca plc (ADR) (AZN) Will Face Pressure from Investors (NYSE:AZN) - October 7 at 8:32 AM
News IconCorrection to AstraZeneca Story (NYSE:AZN) - October 7 at 8:32 AM
News IconOn a Roll, AstraZeneca PLC Licenses Respiratory Drug to Insmed in $150 Million Deal (NYSE:AZN) - October 6 at 8:21 AM logoTune In Sunday For More On Bristol-Myers's Cancer Drug (NYSE:AZN) - October 5 at 3:26 PM logoAstraZeneca Heart Drug Brilinta Fails a Study; Shares Down (NYSE:AZN) - October 5 at 8:35 AM logoAstraZeneca licenses respiratory drug to Insmed (NYSE:AZN) - October 5 at 8:35 AM logoAstraZeneca Drug Trial Failure Has Major Implications To Its Pipeline - Benzinga (NYSE:AZN) - October 4 at 3:43 PM logoAralez To Acquire US Rights To AstraZeneca's Beta Blocker Toprol-XL For $175 Mln - Nasdaq (NYSE:AZN) - October 4 at 3:42 PM logoAstraZeneca's Brilinta Didn't Meet Primary Endpoint - Benzinga (NYSE:AZN) - October 4 at 8:32 AM
News IconActive Mix Cap Retreated Movers- AstraZeneca PLC (NYSE:AZN), TE Connectivity (NYSE:TEL) - Street Wise Report (press release) (blog) (NYSE:AZN) - October 4 at 8:32 AM logoAstra Cuts $3.5 Billion Target for Brilinta After Trial Setback (NYSE:AZN) - October 4 at 8:32 AM logo[$$] AstraZeneca's Brilinta Fails Arterial Disease Drug Trial (NYSE:AZN) - October 4 at 8:32 AM logoInvestor's Guide to This Week's Clovis, Tesaro Ovarian Cancer Drug Updates (NYSE:AZN) - October 4 at 8:32 AM logoAstraZeneca plc (ADR) (NYSE:AZN) Inks License Deal With Allergan plc Ordinary Shares (NYSE:AGN) - TCC (NYSE:AZN) - October 3 at 3:40 PM logoAstraZeneca signs $1.5 bln deal with Allergan - MarketWatch (NYSE:AZN) - October 3 at 8:30 AM


Astrazeneca PLC (NYSE:AZN) Chart for Tuesday, October, 25, 2016

Last Updated on 10/25/2016 by Staff